Drugmakers arguethat peer reviews or real-world evidence of the benefits of theirdrugs should have been included included in the report's analysis.(Photo: ShutterstocK)
Drug manufacturers in 2017 and 2018 hiked the prices of sevendrugs to the tune of $5.1 billion–despite no new clinical evidencethe drugs had improved, according to Institute for Clinical andEconomic Review's Unsupported Price Increase Report.
Drugs with unsupported price increases, according to thenonprofit include, Humira, with a 15.9 percent net price increase,resulting in $1,857 of increased spending; Rituxan, 23.6 percent,$806; Lyrica, 22.2 percent, $688; Truvada, 23.1 percent, $550;Neulasta, 13.4 percent, $489; Cialis, 32.5 percent, $403; andTecfidera, 9.8 percent, $313.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Katie Kuehner-Hebert
Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.
